Immunomodulatory Effects of Fosfomycin in Experimental Human Endotoxemia-Reference-Cited by-同舟云学术

Immunomodulatory Effects of Fosfomycin in Experimental Human Endotoxemia

Published:2007-05 Issue:5 Volume:51 Page:1879-1881
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sauermann Robert¹,Marsik Claudia²,Steiner Ilka¹,Seir Katja¹,Cvitko Tuende²,Zeitlinger Markus¹,Wagner Oswald³,Joukhadar Christian¹⁴

Affiliation:

1. Department of Clinical Pharmacology, Division of Pharmacokinetics

2. Department of Clinical Pharmacology, Division of Immunology and Hematology

3. Institute of Medical and Chemical Laboratory Diagnostics

4. Department of Internal Medicine IV, Division of Pulmology, Medical University of Vienna, Vienna, Austria

Abstract

ABSTRACT To evaluate the effect of fosfomycin on proinflammatory cytokines, a bolus of 2 ng of bacterial lipopolysaccharide/kg of body weight was injected intravenously into healthy volunteers. After 2 h, subjects received 8 g of fosfomycin or placebo in a randomized crossover study design. The resulting concentrations of tumor necrosis factor alpha, interleukin-1β (IL-1β), and IL-6 expressed as protein and mRNA levels were almost identical with and without fosfomycin.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00914-06

Reference22 articles.

1. Abraham, E. 1997. Therapies for sepsis. Emerging therapies for sepsis and septic shock. West. J. Med.166:195-200.

2. Abraham, E., P. F. Laterre, R. Garg, H. Levy, D. Talwar, B. L. Trzaskoma, B. Francois, J. S. Guy, M. Bruckmann, A. Rea-Neto, R. Rossaint, D. Perrotin, A. Sablotzki, N. Arkins, B. G. Utterback, and W. L. Macias. 2005. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med.353:1332-1341.

3. Abraham, E., K. Reinhart, S. Opal, I. Demeyer, C. Doig, A. L. Rodriguez, R. Beale, P. Svoboda, P. F. Laterre, S. Simon, B. Light, H. Spapen, J. Stone, A. Seibert, C. Peckelsen, C. De Deyne, R. Postier, V. Pettila, A. Artigas, S. R. Percell, V. Shu, C. Zwingelstein, J. Tobias, L. Poole, J. C. Stolzenbach, and A. A. Creasey. 2003. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA290:238-247.

4. Arndt, P., and E. Abraham. 2001. Immunological therapy of sepsis: experimental therapies. Intensive Care Med.27(Suppl. 1):S104-S115.

5. Carlet, J. 2001. Immunological therapy in sepsis: currently available. Intensive Care Med.27(Suppl. 1):S93-S103.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fosfomycin mitigated apoptosis while increased mucin secretion in swine intestinal explants challenged by Lawsonia intracellularis;Pharmacological Research - Reports;2024-03

2. Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment;European Respiratory Review;2021-10-05

3. In vitro and in vivo Antibacterial Activity of Linezolid Plus Fosfomycin Against Staphylococcus aureus with Resistance to One Drug;Infection and Drug Resistance;2021-02

Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Galleria mellonella Larval Infection Model

;Infection and Drug Resistance;2019-11

5. Fosfomycine, place et intérêt dans un contexte de multirésistance;Journal des Anti-infectieux;2016-09